Last reviewed · How we verify
Ropivacaine 0.75%, 5ml
At a glance
| Generic name | Ropivacaine 0.75%, 5ml |
|---|---|
| Also known as | Naropin |
| Sponsor | Paracelsus Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of OFA, OSA Versus Opioid-based Anesthesia on NETs and Cancer Cell Malignancy After Colorectal Cancer Surgery (NA)
- Comparison of Continuous ESP Versus TEA After Thoracotomy (NA)
- Comparing Two Regional Anesthesia Interventions for Knee Arthroplasty. (NA)
- Superior Hypogastric Nerve Block for Pain Control Post-uterine Fibroid Embolization (PHASE2)
- Ultrasound-guided Intermediate Cervical Plexus Block (NA)
- Does the Preoperative Midazolam Dose Affect Postoperative Pain? (PHASE4)
- Comparison of the Analgesic Effect of Different Local Anesthetics in Interscalene Nerve Block for Shoulder Surgery (PHASE4)
- Ultrasound Guided Intermediate Cervical Plexus Block and Additional Perivascular Local Anesthetic Infiltration (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ropivacaine 0.75%, 5ml CI brief — competitive landscape report
- Ropivacaine 0.75%, 5ml updates RSS · CI watch RSS
- Paracelsus Medical University portfolio CI